A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia

Jiewen Zhu, Longen Zhou, Guikai Wu, Heiko Konig, Xiaoqin Lin, Guideng Li, Xiao Long Qiu, Chi Fen Chen, Chun Mei Hu, Erin Goldblatt, Ravi Bhatia, A. Richard Chamberlin, Phang Lang Chen, Wen Hwa Lee

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and chronic myeloid leukaemia (CML). Directly targeting RAD51 and attenuating the deregulated RAD51 activity has therefore been proposed as an alternative and supplementary strategy for cancer treatment. Here we show that a newly identified small molecule, IBR2, disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, reduces ionizing radiation-induced RAD51 foci formation, impairs HR, inhibits cancer cell growth and induces apoptosis. In a murine imatinib-resistant CML model bearing the T315I Bcr-abl mutation, IBR2, but not imatinib, significantly prolonged animal survival. Moreover, IBR2 effectively inhibits the proliferation of CD34+ progenitor cells from CML patients resistant to known BCR-ABL inhibitors. Therefore, small molecule inhibitors of RAD51 may suggest a novel class of broad-spectrum therapeutics for difficult-to-treat cancers. A newly identified RAD51 inhibitor leading to degradation of RAD51 via the proteasome pathway inhibits cancer cell survival and greatly increases life spans in a mouse chronic myeloid leukaemia model.

Original languageEnglish (US)
Pages (from-to)353-365
Number of pages13
JournalEMBO Molecular Medicine
Volume5
Issue number3
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Homologous Recombination
Proteasome Endopeptidase Complex
Neoplasms
Cell Survival
Rad51 Recombinase
Breast Neoplasms
Recombinases
Ionizing Radiation
Drug Resistance
Proteolysis
Stem Cells
Cell Proliferation
Imatinib Mesylate
Apoptosis
Mutation
Therapeutics
Growth

Keywords

  • Cancer
  • CML
  • Inhibitor
  • RAD51
  • Small molecule

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. / Zhu, Jiewen; Zhou, Longen; Wu, Guikai; Konig, Heiko; Lin, Xiaoqin; Li, Guideng; Qiu, Xiao Long; Chen, Chi Fen; Hu, Chun Mei; Goldblatt, Erin; Bhatia, Ravi; Chamberlin, A. Richard; Chen, Phang Lang; Lee, Wen Hwa.

In: EMBO Molecular Medicine, Vol. 5, No. 3, 03.2013, p. 353-365.

Research output: Contribution to journalArticle

Zhu, J, Zhou, L, Wu, G, Konig, H, Lin, X, Li, G, Qiu, XL, Chen, CF, Hu, CM, Goldblatt, E, Bhatia, R, Chamberlin, AR, Chen, PL & Lee, WH 2013, 'A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia', EMBO Molecular Medicine, vol. 5, no. 3, pp. 353-365. https://doi.org/10.1002/emmm.201201760
Zhu, Jiewen ; Zhou, Longen ; Wu, Guikai ; Konig, Heiko ; Lin, Xiaoqin ; Li, Guideng ; Qiu, Xiao Long ; Chen, Chi Fen ; Hu, Chun Mei ; Goldblatt, Erin ; Bhatia, Ravi ; Chamberlin, A. Richard ; Chen, Phang Lang ; Lee, Wen Hwa. / A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. In: EMBO Molecular Medicine. 2013 ; Vol. 5, No. 3. pp. 353-365.
@article{14f57e120f9f41a3b6459f77c3e5d6a1,
title = "A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia",
abstract = "RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and chronic myeloid leukaemia (CML). Directly targeting RAD51 and attenuating the deregulated RAD51 activity has therefore been proposed as an alternative and supplementary strategy for cancer treatment. Here we show that a newly identified small molecule, IBR2, disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, reduces ionizing radiation-induced RAD51 foci formation, impairs HR, inhibits cancer cell growth and induces apoptosis. In a murine imatinib-resistant CML model bearing the T315I Bcr-abl mutation, IBR2, but not imatinib, significantly prolonged animal survival. Moreover, IBR2 effectively inhibits the proliferation of CD34+ progenitor cells from CML patients resistant to known BCR-ABL inhibitors. Therefore, small molecule inhibitors of RAD51 may suggest a novel class of broad-spectrum therapeutics for difficult-to-treat cancers. A newly identified RAD51 inhibitor leading to degradation of RAD51 via the proteasome pathway inhibits cancer cell survival and greatly increases life spans in a mouse chronic myeloid leukaemia model.",
keywords = "Cancer, CML, Inhibitor, RAD51, Small molecule",
author = "Jiewen Zhu and Longen Zhou and Guikai Wu and Heiko Konig and Xiaoqin Lin and Guideng Li and Qiu, {Xiao Long} and Chen, {Chi Fen} and Hu, {Chun Mei} and Erin Goldblatt and Ravi Bhatia and Chamberlin, {A. Richard} and Chen, {Phang Lang} and Lee, {Wen Hwa}",
year = "2013",
month = "3",
doi = "10.1002/emmm.201201760",
language = "English (US)",
volume = "5",
pages = "353--365",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia

AU - Zhu, Jiewen

AU - Zhou, Longen

AU - Wu, Guikai

AU - Konig, Heiko

AU - Lin, Xiaoqin

AU - Li, Guideng

AU - Qiu, Xiao Long

AU - Chen, Chi Fen

AU - Hu, Chun Mei

AU - Goldblatt, Erin

AU - Bhatia, Ravi

AU - Chamberlin, A. Richard

AU - Chen, Phang Lang

AU - Lee, Wen Hwa

PY - 2013/3

Y1 - 2013/3

N2 - RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and chronic myeloid leukaemia (CML). Directly targeting RAD51 and attenuating the deregulated RAD51 activity has therefore been proposed as an alternative and supplementary strategy for cancer treatment. Here we show that a newly identified small molecule, IBR2, disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, reduces ionizing radiation-induced RAD51 foci formation, impairs HR, inhibits cancer cell growth and induces apoptosis. In a murine imatinib-resistant CML model bearing the T315I Bcr-abl mutation, IBR2, but not imatinib, significantly prolonged animal survival. Moreover, IBR2 effectively inhibits the proliferation of CD34+ progenitor cells from CML patients resistant to known BCR-ABL inhibitors. Therefore, small molecule inhibitors of RAD51 may suggest a novel class of broad-spectrum therapeutics for difficult-to-treat cancers. A newly identified RAD51 inhibitor leading to degradation of RAD51 via the proteasome pathway inhibits cancer cell survival and greatly increases life spans in a mouse chronic myeloid leukaemia model.

AB - RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and chronic myeloid leukaemia (CML). Directly targeting RAD51 and attenuating the deregulated RAD51 activity has therefore been proposed as an alternative and supplementary strategy for cancer treatment. Here we show that a newly identified small molecule, IBR2, disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, reduces ionizing radiation-induced RAD51 foci formation, impairs HR, inhibits cancer cell growth and induces apoptosis. In a murine imatinib-resistant CML model bearing the T315I Bcr-abl mutation, IBR2, but not imatinib, significantly prolonged animal survival. Moreover, IBR2 effectively inhibits the proliferation of CD34+ progenitor cells from CML patients resistant to known BCR-ABL inhibitors. Therefore, small molecule inhibitors of RAD51 may suggest a novel class of broad-spectrum therapeutics for difficult-to-treat cancers. A newly identified RAD51 inhibitor leading to degradation of RAD51 via the proteasome pathway inhibits cancer cell survival and greatly increases life spans in a mouse chronic myeloid leukaemia model.

KW - Cancer

KW - CML

KW - Inhibitor

KW - RAD51

KW - Small molecule

UR - http://www.scopus.com/inward/record.url?scp=84874692588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874692588&partnerID=8YFLogxK

U2 - 10.1002/emmm.201201760

DO - 10.1002/emmm.201201760

M3 - Article

C2 - 23341130

AN - SCOPUS:84874692588

VL - 5

SP - 353

EP - 365

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 3

ER -